Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14456MR)

This product GTTS-WQ14456MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14456MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2490MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ11601MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ15944MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ13362MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1733MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ7733MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ3407MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ11753MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW